Porcine CXCR1/2 antagonist CXCL8(3–72)G31P inhibits lung inflammation in LPS-challenged mice

Xue Wang,Yanchuan Li,Lintao Li,Zhe Jiao,Xiaoli Liu,Guofu Cheng,Changqin Gu,Xueying Hu,Wanpo Zhang
DOI: https://doi.org/10.1038/s41598-020-57737-w
IF: 4.6
2020-01-27
Scientific Reports
Abstract:Abstract Swine pneumonia is a great threat for pig industry around the world, which is usually accompanied with neutrophils infiltration in the airway. Although interleukin-8 (CXCL8) and its receptors, CXC chemokine receptor 1 and 2 (CXCR1/2) in human have been well documented, the expression and function of CXCR1/2 is still unknown in swine. To explore the feasibility to develop new veterinary anti-inflammatory drugs targeting porcine CXCR1/2, we detected CXCR1/2 expression in swine pneumonia through Real-Time PCR and immunohistochemistry for the first time. Two porcine CXCR1/2 antagonists, CXCL8 (3–72) N11R/G31P (pN11R) and CXCL8 (3–72) G31P (pG31P) were prepared and their anti-inflammatory effects were evaluated using cell chemotaxis assays and animal experiments. Our data showed that CXCR1/2 expression, which was closely related to neutrophil infiltration in the lung, was significantly up-regulated in swine pneumonia. The pN11R and pG31P could effectively inhibit the directional migration of neutrophils in vitro . In vivo data also indicated that both pN11R and pG31P significantly relieved LPS-induced pneumonia in mice through decreasing the expression of TNF-α , CXCL8 , and IL-1β , and inhibiting neutrophil influx into the lung. pG31P was more efficient. Our study suggested that it is possible to develop new veterinary anti-inflammatory drugs targeting porcine CXCR1/2, and pG31P is a promising candidate.
multidisciplinary sciences
What problem does this paper attempt to address?